Table 1.
Clinical and Laboratory Characteristics of 142 Patients
| Characteristic | Estimate or Median | Percentage or Range |
|---|---|---|
| Sex: female (%) | 78 | 55 |
| Age, y | 36.00 | 16.00–72.00 |
| Self-identified “race” or ethnic group | ||
| Mixed race South African | 127 | 89% |
| Black South African | 15 | 11% |
| Weight, kg | ||
| Weight | 46.00 | 28.00–85.50 |
| Weight change with 2 months of therapy | 8.37 | −11.55 to 36.84 |
| Human immunodeficiency virus infection, % | 15 | 10 |
| Dose and range, mg/kg | ||
| Rifampin | 10.90 | 7.02–15.79 |
| Isoniazid | 6.52 | 3.51–10.53 |
| Pyrazinamide | 35.71 | 19.69–52.63 |
| Ethambutol | 24.62 | 12.88–34.12 |
| Received streptomycin, % | 68 | 47.89% |
| Prior tuberculosis, % | 91 | 64 |
| Symptoms at time of pharmacokinetic sampling | ||
| Resolved | 50 | 35.21% |
| Improved | 81 | 57.04% |
| Chest x-ray changes | ||
| Improved/resolved | 120 | 84.51% |
| No improvement/worse | 22 | 15.49% |
| Slow acetylators, %a | 17 | 18.30% |
| Hemoglobin, g/dL (range) | 11.90 | 7.4–14.90 |
| White cell count, ×109 cells/mL | 8.45 | 3.40–25.70 |
| Platelet count, ×109 cells/mL | 408.0 | 66.0–849.0 |
| Erythrocyte sedimentation rate, mm/h | 51.00 | 1.0–138.0 |
| Creatinine clearance rate, mL/min (range) | 72.65 | 20.12–128.90 |
| Total protein, g/L | 78.00 | 62–114 |
| Albumin, g/L | 34.00 | 19–47 |
| Elevated liver function testb (% patients) | 8 | 6 |
Creatinine clearance rate was calculated using the Cockcroft–Gault equation.
a Acetylation phenotype and genotype tests were performed on the first 93 patients.
b At least >1.5 normal for either alanine aminotransferase (1 patient) or aspartate aminotransferase (2 patients) or alkaline phosphatase (5 patients); no patient had >2 times upper limit of normal of any of the 3 enzymes.